A Phase I, Open Label, Multicenter Study to Assess the Safety, Tolerability and Pharmacology of AZD2281 in Combination With Liposomal Doxorubicin (Caelyx®) in Patients With Advanced Solid Tumors
Interventional
Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
recommended dose
2 months
Yes
Jane Robertson, BSc, MBCHB, MD
Study Director
AstraZeneca
Italy: National Monitoring Centre for Clinical Trials - Ministry of Health
D0810L00001
NCT00819221
January 2009
August 2013
Name | Location |
---|